Analyst Ratings For Asterias Biotherapeutics (NYSE:AST)
Today, HC Wainwright reiterated its Buy rating on Asterias Biotherapeutics (NYSE:AST) with a price target of $12.00.
There are 2 buy ratings on the stock.
The current consensus rating on Asterias Biotherapeutics (NYSE:AST) is Buy (Score: 3.00) with a consensus target price of $12.00 per share, a potential 233.33% upside.
Some recent analyst ratings include
- 10/2/2017-HC Wainwright Reiterated Rating of Buy.
- 4/4/2017-Laidlaw initiated coverage with a Buy rating.
Recent Trading Activity for Asterias Biotherapeutics (NYSE:AST)
Shares of Asterias Biotherapeutics closed the previous trading session at with shares trading hands.